Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma

American Journal of Cancer Research

Volumn 5, Issue 9, 2015, Pages 2838-2848

  Campbell, Lee ^a,b   Jasani, Bharat ^a   Griffiths, David F R ^a   Gumbleton, Mark ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

4E BP1; Biomarker; CcRCC; Clear cell renal cell carcinoma; EIF4E; Immunohistochemistry; Metastatic disease; MTOR; Prognosis; Stratification

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TISSUE MICROARRAY; VERY ELDERLY;

EID: 85006210375     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Stewart GD, O'Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D. What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol 2011; 8: 255-265.
2. Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, White E. Risk factors for renal cell carcinoma in the VITAL study. J Urol 2013; 190: 1657-1661.
3. Smaldone MC, Uzzo RG. Active surveillance: a potential strategy for select patients with small renal masses. Future Oncol 2011; 7: 1133-1147.
4. Goyal R, Gersbach E, Yang XJ, Rohan SM. Differential diagnosis of renal tumors with clear cytoplasm: clinical relevance of renal tumor subclassification in the era of targeted therapies and personalized medicine. Arch Pathol Lab Med 2013; 137: 467-480.
5. Rink M, Chun FK, Robinson B, Sun M, Karakiewicz PI, Bensalah K, Fisch M, Scherr DS, Lee RK, Margulis V, Shariat SF. Tissue-based molecular markers for renal cell carcinoma. Minerva Urol Nefrol 2011; 63: 293-308.
6. Maroto P, Rini B. Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res 2014; 20: 2060-2071.
7. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DGB, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a vicious cycle. Sci Transl Med 2013; 5: 196.
8. Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Sehouli J, Dietel M, Denkert C. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 2008; 20: 1409-1417.
9. Korkolopoulou P, Levidou G, El-Habr EA, Piperi C, Adamopoulos C, Samaras V, Boviatsis E, Thymara I, Trigka E-A, Sakellariou S, Kavantzas N, Patsouris E, Saetta AA. Phosphorylated 4Ebinding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. Histopathology 2012; 61: 293-305.
10. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, Hurst BM, Deddens JA, Neubauer BA, Stancato LF, Carter HW, Douglass LA, Carter JH. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009; 69: 3866-3873.
11. Jia Y, Polunovsky V, Bitterman PB, Wagner CR. Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target. Med Res Rev 2012; 32: 786-814.
12. Villalonga P, Fernández de Mattos S, Ridley AJ. RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation. J Biol Chem 2009; 284: 35287-35296.
13. Lee T, Pelletier J. Eukaryotic initiation factor 4F: a vulnerability of tumor cells. Future Med Chem 2012; 4: 19-31.
14. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10: 484-486.
15. Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF, Xia LP. Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol 2011; 28: 1302-1307.
16. Choi CH, Lee JS, Kim SR, Lee YY, Kim CJ, Lee JW, Kim TJ, Lee JH, Kim BG, Bae DS. Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol 2011; 137: 463-469.
17. Salehi Z, Mashayekhi F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem 2006; 39: 404-409.
18. Heikkinen T, Korpela T, Fagerholm R, Khan S, Aittomaki K, Heikkila P, Blomqvist C, Carpen O, Nevanlinna H. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment. Breast Cancer Res Tr 2013; 141: 79-88.
19. Wang XL, Cai HP, Ge JH, Su XF. Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol 2012; 18: 2540-2544.
20. Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther 2012; 13: 272-280.
21. Martineau Y, Azar R, Bousquet C, Pyronnet S. Anti-oncogenic potential of the eIF4E-binding proteins. Oncogene 2013; 32: 671-677.
22. Griffiths DFR, Verghese A, Golash A, Kynaston HG, Matthews PN, Hart AJL, Court JB. Contribution of grade, vascular invasion and age to outcome in clinically localized renal cell carcinoma. BJU Int 2002; 90: 26-31.
23. Campbell L, Gumbleton M, Griffiths DFR. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 2003; 89: 1909-1913.
24. Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DFR. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer 2008; 98: 931-940.
25. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663.
26. Thomas DH, Verghese A, Kynaston HG, Griffiths DFR. Analysis of the prognostic implications of different tumour margin types in renal cell carcinoma. Histopathology 2003; 43: 374-380.
27. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011; 16 Suppl 2: 4-13.
28. Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V, Verghese ET, McElwaine JN, Hughes TA. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 2009; 100: 1393-1399.
29. Zhao WT, Zhou CF, Li XB, Zhang YF, Fan L, Pelletier J, Fang J. The von Hippel-Lindau protein pVHL inhibits ribosome biogenesis and protein synthesis. J Biol Chem 2013; 288: 16588-16597.
30. Borden KL. Targeting the oncogene eIF4E in cancer: From the bench to clinical trials. Clin Invest Med 2011; 34: E315.
31. Seki N, Takasu T, Sawada S, Nakata M, Nishimura R, Segawa Y, Shibakuki R, Hanafusa T, Eguchi K. Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer 2010; 70: 329-334.
32. Yamaguchi S, Yoshihiro S, Matsuyama H, Nagao K, Fukunaga K, Matsumoto H, Matsuda K, Oba K, Naito K. The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. Clinical Genetics 2003; 63: 184-191.
33. Tang SW, Chang WH, Su YC, Chen YC, Lai YH, Wu PT, Hsu CI, Lin WC, Lai MK, Lin JY. MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett 2009; 273: 35-43.
34. Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene 2004; 23: 3217-3221.
35. Nishikawa M, Miyake H, Harada KI, Fujisawa M. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Med Oncol 2014; 31: 792.
36. Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR. mTORC1 drives HIF-1a and VEGF-A signalling via multiple mechanisms involving 4EBP1, S6K1 and STAT3. Oncogene 2014; 34: 2239-2250.
37. Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Rashid G, Lishner M. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Invest 2012; 92: 178-190.